Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „tocilizumab“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.8 · In 6-month controlled clinical trials, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was
Eintrag öffnenRoActemra · 4.8 · In SC-II, a total of 434 patients treated with tocilizumab 162 mg every other week were tested for anti- tocil
Eintrag öffnenRoActemra · 4.8 · In SC-II, a total of 434 patients treated with tocilizumab 162 mg every other week were tested for anti- tocil
Eintrag öffnenRoActemra · 4.8 · In the 12 week controlled phase, 16 % of patients in the tocilizumab group and 5.4 % of patients in the placeb
Eintrag öffnenRoActemra · 4.8 · In the 12 week controlled phase, the rate of serious infections in the intravenous tocilizumab group was 11.5
Eintrag öffnenRoActemra · 4.8 · Infections In the 12 week controlled phase, the rate of all infections in the intravenous tocilizumab group wa
Eintrag öffnenRoActemra · 4.8 · Infections In the 6-month controlled trials the rate of all infections reported with tocilizumab 8 mg/kg plus
Eintrag öffnenRoActemra · 4.8 · Infections In the 6-month controlled trials the rate of all infections reported with tocilizumab 8 mg/kg plus
Eintrag öffnenRoActemra · 4.8 · Infections In the subcutaneous tocilizumab trial, the rate of infection in pJIA patients treated with subcutan
Eintrag öffnenRoActemra · 4.8 · Infections In the subcutaneous tocilizumab trial, the rate of infection in pJIA patients treated with subcutan
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection in sJIA patients treated with subcutaneous tocilizumab was comparable to sJIA
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection in sJIA patients treated with subcutaneous tocilizumab was comparable to sJIA
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection/serious infection events was balanced between the tocilizumab weekly group (2
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection/serious infection events was balanced between the tocilizumab weekly group (2
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infections in the tocilizumab all exposure population was 163.7 per 100 patient years.
Eintrag öffnenRoActemra · 4.8 · Injection site reactions A total of 28.8 % (15/52) pJIA patients experienced ISRs to tocilizumab subcutaneous.
Eintrag öffnenRoActemra · 4.8 · Injection site reactions In the tocilizumab subcutaneous weekly group, a total of 6 % (6/100) patients reporte
Eintrag öffnenRoActemra · 4.8 · Laboratory abnormalities During routine laboratory monitoring in the tocilizumab all exposure population, a de
Eintrag öffnenRoActemra · 4.8 · Laboratory abnormalities During routine laboratory monitoring in the tocilizumab all exposure population, a de
Eintrag öffnenRoActemra · 4.8 · Lipid parameters During routine laboratory monitoring in the intravenous tocilizumab Trial WA19977 3.4 % and 1
Eintrag öffnen